Summit Therapeutics Inc. filed a Form 8-K on November 18, 2026, announcing the planned initiation of the global Phase III HARMONi-10 clinical trial evaluating ivonescimab in locally advanced, unresectable Stage III non-small cell lung cancer.
Key Highlights
- New Phase III trial: Summit Therapeutics disclosed the planned initiation of the global Phase III HARMONi-10 trial, according to the filing.
- Comparator drug: HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy, the company disclosed.
- Patient population: The trial targets patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not experienced disease progression following platinum-based concurrent chemoradiation therapy.
- Site activation timeline: Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026, per the filing.
- Announcement vehicle: The disclosure was made via a press release dated November 18, 2026, attached as Exhibit 99.1 to the filing.
Summit Therapeutics Discloses HARMONi-10 Trial Design and Initiation Plans
Summit Therapeutics Inc. (NASDAQ:SMMT) filed a current report on Form 8-K dated November 18, 2026, under Item 8.01 (Other Events), disclosing that the company issued a press release announcing the planned initiation of its global Phase III HARMONi-10 trial. The trial is designed to evaluate ivonescimab compared with durvalumab as consolidation therapy in a specific patient population.
According to the filing, HARMONi-10 will enroll patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. The company described the study as a global clinical trial, with site activations expected to begin in the fourth quarter of 2026. The filing did not specify the number of planned enrollment sites, total patient enrollment targets, or primary endpoints beyond what is stated above.
The 8-K was signed by Manmeet S. Soni, identified in the filing as Chief Operating Officer, Chief Financial Officer, and Director, serving as Principal Financial Officer. The company noted that the press release, dated November 18, 2026, is attached as Exhibit 99.1 and incorporated by reference into the current report. The filing also includes a Cover Page Interactive Data File embedded within the Inline XBRL document as Exhibit 104. The filing contains forward-looking statements regarding trial initiation timelines, which are the company's own and subject to its cautionary language.
What Was Disclosed
Summit Therapeutics filed an 8-K on November 18, 2026, announcing plans to initiate the global Phase III HARMONi-10 trial comparing ivonescimab with durvalumab in Stage III non-small cell lung cancer patients, with site activations expected in the fourth quarter of 2026.



Please wait processing your request...